Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Friday: The FDA Drops the Hammer On February 6th, one day after the HIMS launch, FDA Commissioner Martin Makary issued a statement that may be the most consequential regulatory action in the compounded GLP-1 saga to date
Cytotherapy 8 (4), 315317
Your provider may recommend additional cycles based on your goals, lab results, and your response, allowing for flexibility throughout your wellness journey
Recently, we highlighted two small molecule leaders in the GLP-1R agonism space, orforglipron and danuglipron
The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19
GLP-1s (short for glucagon-like peptide-1 receptor agonists ) are medications originally developed to treat type 2 diabetes and have been in use since 2005
